DigestRedComo funciona
Red
/
Empresas
Im
No verificado

ImmunityBio, Inc.

Sobre qué escribimos

BiotecnologíaFarmacéuticaMedicina - VariosOncologíaSalud

51 Comunicados de prensa

Ver todos los comunicados de prensa
23/01/2026
ImmunityBio Reports Median Overall Survival Not Yet Reached and Lymphopenia Reversed in Recurrent Glioblastoma Patients Receiving ANKTIVA® Plus CAR-NK, Chemo-Free Therapy
Fuente
ImmunityBio, Inc.
Editor
Business Wire
1.00
0
16/01/2026
ImmunityBio Announces Durable Complete Response of 15 Months with a Chemotherapy-Free CD19 CAR-NK Cell Therapy in Waldenstrom Lymphoma
Fuente
ImmunityBio, Inc.
Editor
Business Wire
1.00
0
16/01/2026
Biotecnología
Salud
Farmacéutica
Medicina - Varios
Oncología
Industria
ImmunityBio Advances First-Line BCG Naive NMIBC Program with Enrollment Exceeding Expectations and Positive Interim Analysis for ANKTIVA® Plus BCG
Fuente
ImmunityBio, Inc.
Editor
Business Wire
1.00
0
15/01/2026
Biotecnología
Farmacéutica
Salud
Oncología
ImmunityBio Reports Continued Execution and Sales Momentum With $113 Million of Preliminary Net Product Revenue—a 700% increase year-over-year
Fuente
ImmunityBio, Inc.
Editor
Business Wire
1.00
0
14/01/2026
Biotecnología
Farmacéutica
Salud
Oncología
Industria
Saudi FDA Grants Accelerated Approval to ImmunityBio’s ANKTIVA® for Non-Muscle Invasive Bladder Cancer with Carcinoma In-Situ
Fuente
ImmunityBio, Inc.
Editor
Business Wire
1.00
0
13/01/2026
Industria
Biotecnología
Salud
Farmacéutica
Medicina - Varios
Oncología
ImmunityBio Announces Positive Results Demonstrating ANKTIVA® as a Lymphocyte Stimulating Agent in Combination With Checkpoint Inhibitors in Non-Small Cell Lung Cancer
Fuente
ImmunityBio, Inc.
Editor
Business Wire
1.00
0
12/01/2026
Mercado laboral
Eventos
Industria
Biotecnología
VIH, SIDA y enfermedades autoinmunes
Salud
Farmacéutica
Oncología
NantWorks and ImmunityBio Announce Inaugural U.S.-Saudi Biotech Alliance Summit to Advance Immunotherapy 2.0 and Global Health Security
Fuente
ImmunityBio, Inc.
Editor
Business Wire
1.00
0
29/12/2026
Ciencia
Biotecnología
Farmacéutica
Oncología
Salud
VIH, SIDA y enfermedades autoinmunes
Medicina - Varios
Mercado laboral
Eventos
ImmunityBio Founder Dr. Patrick Soon-Shiong Recognized as One of “100 Most Influential People in Oncology in 2025”
Fuente
ImmunityBio, Inc.
Editor
Business Wire
1.00
0
16/12/2025
Industria
Biotecnología
Salud
Farmacéutica
Medicina - Varios
Oncología
ANKTIVA® with BCG Demonstrates 96% Survival from Bladder Cancer at Three Years with Median Survival Not Yet Reached in BCG-Unresponsive High-Grade Papillary-Only Non-Muscle Invasive Bladder Cancer
Fuente
ImmunityBio, Inc.
Editor
Business Wire
1.00
0
13/11/2025
Análisis de Mercados
Industria
Ciencia
VIH, SIDA y enfermedades autoinmunes
Medicina - Varios
Sanidad
Biotecnología
Farmacéutica
Salud
Oncología
New Survey Reveals Non-Muscle Invasive Bladder Cancer Patients Seek More Care Conversations
Fuente
ImmunityBio, Inc.
Editor
Business Wire
1.00
0

Detalles de contacto

Redes sociales

Seguidores
0
Compatibilidad
0